(Dexamethasone Tablets, USP)
DECADRON (dexamethasone tablets, USP) tablets, for oral administration, are supplied in two potencies, 0.5 mg and 0.75 mg.
Decadron (dexamethasone) is indicated for the following:
Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness.
Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis.
Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia.
Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic diseases: For the palliative management of leukemias and lymphomas.
Nervous system: Acute exacerbations of multiple sclerosis, cerebral edemaassociated with primary or metastatic brain tumor, craniotomy, or head injury.
Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
Media Articles Related to Decadron (Dexamethasone)
The impact of dexamethasone on intelligence and hearing in preterm infants
Source: Hearing / Deafness News From Medical News Today [2014.09.08]
Glucocorticoids are speculated to have a long-term impact on the development of the nervous system and increase the incidence of cerebral palsy in preterm infants.
Published Studies Related to Decadron (Dexamethasone)
Dexamethasone and long-term survival in bacterial meningitis. 
bacterial meningitis are lacking... CONCLUSIONS: In adults with community-acquired bacterial meningitis, the survival
Randomized, double-blind, placebo-controlled, phase III cross-over study
evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3
receptor antagonist and dexamethasone in patients with germ cell tumors receiving
5-day cisplatin combination chemotherapy regimens: a hoosier oncology group
of cisplatin combination chemotherapy for testicular cancer... CONCLUSION: There was a significant improvement in CR rate with aprepitant
Dexamethasone versus ondansetron in combination with dexamethasone for the
prophylaxis of postoperative vomiting in pediatric outpatients: a double-blind,
randomized, placebo-controlled clinical trial. 
incidence of which ranges from 8.9% to 42%... CONCLUSIONS: The prophylactic use of antiemetic drugs failed to reduce the
Efficacy comparison of periapical infiltration injection of dexamethasone,
morphine and placebo for postoperative endodontic pain. 
CONCLUSION: Periapical infiltration of dexamethasone and morphine led to a
Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. 
concentrations in the patients... CONCLUSION: Dexamethasone ointment was efficient in the treatment of recurrent
Clinical Trials Related to Decadron (Dexamethasone)
Dexamethasone for Paediatric Adeno-Tonsillectomy - A Dose-Finding Study [Terminated]
Adeno-tonsillectomy is a commonly performed surgical procedure in children. Main morbidities
are postoperative pain, nausea and vomiting, and haemorrhage. Non-steroidal anti-inflammatory
drugs (NSAIDs)widely used for paincontrol increase the risk of postoperative bleeding and
reoperation. Dexamethasone is an powerful antiemetic and has shown analgesic efficacy.
Antiemetic and analgesic dose-response has never been established.
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors [Completed]
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone
(Decadron) a common treatment for symptoms of brain swelling (edema). This study is
specifically aimed at patients who require chronic high doses of dexamethasone to manage
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy [Recruiting]
Background: Dexamethasone is a steroid, which is often given into the vein before
chemotherapy to help control acute nausea and vomiting. It can also be given as an oral
tablet for patients to take for the two days following chemotherapy to help minimise delayed
nausea and vomiting. In chemotherapy regimens that cause high rates of nausea and vomiting,
the use of dexamethasone is well proven. However, in chemotherapy regimens that generally
cause only minimal to moderate rates of nausea and vomiting, the value of oral dexamethasone
in the 48-hour period after chemotherapy is not well proven, although it is often
prescribed. While dexamethasone does decrease nausea, it causes additional side-effects
such as insomnia, indigestion, anxiety and mood changes. While patients with less vomiting
and nausea are expected to have better quality of life (QOL), for patients with minimal
nausea or vomiting, their QOL might be more affected by the side effects of the
dexamethasone treatment than by the nausea.
Study Design: The study will be performed in patients who will be receiving first line
chemotherapy treatment with a moderate risk of nausea/vomiting. Anti-nausea therapy for
acute nausea/vomiting will be standardised and all patients will receive non-steroidal
medication for delayed nausea control. Each patient will be randomly allocated to receive
either oral dexamethasone or an identical appearing placebo tablet for two days after
chemotherapy for the first cycle of chemotherapy, and then crossed over to the other
treatment for the second cycle. Patients will complete QOL assessments, dexamethasone
symptom and nausea and vomiting questionnaires, as well as nausea/vomiting diaries. This
will enable the researchers to determine the effect of dexamethasone on nausea and vomiting
and the impact of both the side effects of dexamethasone, and of nausea and vomiting, on
Objectives: The primary objectives are to determine patient preference for dexamethasone or
placebo, and to compare changes in QOL after chemotherapy in patients who receive
dexamethasone with those who receive placebo. The secondary objectives are: (1) to compare
complete protection from delayed vomiting and severity of nausea; (2) to compare differences
in the impact of nausea and vomiting on QOL, and (3) to compare differences in symptoms that
have been associated with dexamethasone (insomnia, anxiety, agitation, mood, etc.) between
patients receiving dexamethasone and those receiving placebo.
Significance: This study will provide data to evaluate whether the benefits of dexamethasone
for delayed nausea and vomiting outweigh potential side effects in patients receiving
chemotherapy with a moderate risk of causing nausea and vomiting. This addresses a problem
that is important to a majority of patients receiving anticancer chemotherapy. If overall
QOL is improved on dexamethasone, then it should be prescribed more frequently, but if QOL
is reduced on dexamethasone, and patients prefer the placebo, then its use as an anti-nausea
medication for delayed nausea after moderately nauseating chemotherapy should be limited to
patients with poor initial control of nausea/vomiting.
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy [Recruiting]
We hypothesize that the combination of aprepitant with dexamethasone will provide
significantly improved prophylaxis against Postoperative nausea and vomiting compared with
the combination of ondansetron and dexamethasone, in patients undergoing craniotomy under
Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [Completed]
The purpose of this study is to determine how well newly diagnosed multiple myeloma patients
respond to an experimental regimen of Vincristine, DOXIL (doxorubicin HCl liposome injection)
and Dexamethasone (VDD) versus the standard treatment of Vincristine, Doxorubicin and
Reports of Suspected Decadron (Dexamethasone) Side Effects
Renal Failure Acute (21),
Platelet Count Decreased (18), more >>
Page last updated: 2014-09-08